MAbLaunch is a joint bioproduction platform combining LFB Biomanufacturing (LFB) and BioLaunch (Sanofi) capabilities in the field of contract development and manufacturing services.
The platform is supported by a collaboration agreement between Sanofi and LFB based on the synergy of their respective industrial capacities and provides the widest range of CMO services to customers in the most flexible manner.
Mammalian cell culture capacities :
- LFB Biomanufacturing : up to 1,000L
- BioLaunch : Up to 3x 10,000L